Sabine Kopp, PhD
World Health Organization
Medicines Quality Assurance
Sabine Kopp is Group Lead of WHO’s Medicines Quality Assurance. She was, inter alia, Secretary for the International Nonproprietary Names (INN) Programme, Acting Team Coordinator for Quality Assurance and Safety of Medicines, Programme Manager for the Quality Assurance and the Anticounterfeiting programmes, Acting Secretary of the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) and was also actively involved in the WHO Member State mechanism on Substandard/spurious/falsely-labelled/falsified/counterfeit medical products.
Sabine Kopp is Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations and is responsible for the coordination of WHO's activities related to the development and maintenance of international guidelines, GXPs, standards and norms related to Medicines Quality Assurance and the International Pharmacopoeia, i.e. the normative work related to Medicines Quality Assurance within WHO, spanning from development and manufacturing to the distribution and supply of the medicines. She is overseeing WHO’s External Quality Assurance Assessment Scheme for quality control laboratories, serving as Secretary the international meetings of world pharmacopoeias and involved in WHO activities aimed at enabling synergies and convergence in medicines quality assurance.
Sabine Kopp is Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations and is responsible for the coordination of WHO's activities related to the development and maintenance of international guidelines, GXPs, standards and norms related to Medicines Quality Assurance and the International Pharmacopoeia, i.e. the normative work related to Medicines Quality Assurance within WHO, spanning from development and manufacturing to the distribution and supply of the medicines. She is overseeing WHO’s External Quality Assurance Assessment Scheme for quality control laboratories, serving as Secretary the international meetings of world pharmacopoeias and involved in WHO activities aimed at enabling synergies and convergence in medicines quality assurance.